Hybrid red blood cell membrane coated porous silicon nanoparticles functionalized with cancer antigen induce depletion of T cells

Erythrocyte-based drug delivery systems have been investigated for their biocompatibility, long circulation time, and capability to transport cargo all around the body, thus presenting enormous potential in medical applications. In this study, we investigated hybrid nanoparticles consisting of nano-sized autologous or allogeneic red blood cell (RBC) membranes encapsulating porous silicon nanoparticles (PSi NPs). These NPs were functionalized with a model cancer antigen TRP2, which was either expressed on the surface of the RBCs by a cell membrane-mimicking block copolymer polydimethylsiloxane-b-poly-2-methyl-2-oxazoline, or attached on the PSi NPs, thus hidden within the encapsulation. When in the presence of peripheral blood immune cells, these NPs resulted in apoptotic cell death of T cells, where the NPs having TRP2 within the encapsulation led to a stronger T cell deletion. The deletion of the T cells did not change the relative proportion of CD4+ and cytotoxic CD8+ T cells. Overall, this work shows the combination of nano-sized RBCs, PSi, and antigenic peptides may have use in the treatment of autoimmune diseases.

[1]  J. Heino,et al.  Preparation and in vivo evaluation of red blood cell membrane coated porous silicon nanoparticles implanted with 155Tb. , 2020, Nuclear medicine and biology.

[2]  Y. Luan,et al.  Site-specific MOF-based immunotherapeutic nanoplatforms via synergistic tumor cells-targeted treatment and dendritic cells-targeted immunomodulation. , 2020, Biomaterials.

[3]  B. Liu,et al.  An erythrocyte membrane coated mimetic nano-platform for chemo-phototherapy and multimodal imaging , 2019, RSC advances.

[4]  Y. Luan,et al.  A Three-in-One Immunotherapy Nanoweapon via Cascade-Amplifying Cancer-Immunity Cycle against Tumor Metastasis, Relapse and Postsurgical Regrowth. , 2019, Nano letters.

[5]  H. Santos,et al.  Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor , 2019, ACS nano.

[6]  Mingshui Chen,et al.  Exosomes derived from rAAV/AFP-transfected dendritic cells elicit specific T cell-mediated immune responses against hepatocellular carcinoma , 2018, Cancer management and research.

[7]  J. Lahann,et al.  Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude , 2018, Nature Communications.

[8]  Jing Su,et al.  Preparation and characterization of erythrocyte membrane cloaked PLGA/arsenic trioxide nanoparticles and evaluation of their in vitro anti-tumor effect , 2018, RSC advances.

[9]  H. Santos,et al.  Bioengineered Porous Silicon Nanoparticles@Macrophages Cell Membrane as Composite Platforms for Rheumatoid Arthritis , 2018 .

[10]  H. Santos,et al.  Cell Membrane-Based Nanoreactor To Mimic the Bio-Compartmentalization Strategy of a Cell , 2018, ACS biomaterials science & engineering.

[11]  Mónica P. A. Ferreira,et al.  Drug-Loaded Multifunctional Nanoparticles Targeted to the Endocardial Layer of the Injured Heart Modulate Hypertrophic Signaling. , 2017, Small.

[12]  A. Gaur,et al.  Membrane Remodelling and Vesicle Formation During Ageing of Human Red Blood Cells , 2017, Cellular Physiology and Biochemistry.

[13]  Ronnie H. Fang,et al.  Erythrocyte–Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization , 2017, Advanced materials.

[14]  H. Lodish,et al.  Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease , 2017, Proceedings of the National Academy of Sciences.

[15]  H. Santos,et al.  Biomimetic Engineering Using Cancer Cell Membranes for Designing Compartmentalized Nanoreactors with Organelle‐Like Functions , 2017, Advanced materials.

[16]  Jarno Salonen,et al.  Multistaged Nanovaccines Based on Porous Silicon@Acetalated Dextran@Cancer Cell Membrane for Cancer Immunotherapy , 2017, Advanced materials.

[17]  Samir Mitragotri,et al.  Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems. , 2016, Advanced drug delivery reviews.

[18]  H. Santos,et al.  Angiopep2-functionalized polymersomes for targeted doxorubicin delivery to glioblastoma cells. , 2016, International journal of pharmaceutics.

[19]  Jarno Salonen,et al.  In vitro and in vivo assessment of heart-homing porous silicon nanoparticles. , 2016, Biomaterials.

[20]  Ronnie H. Fang,et al.  Safe and Immunocompatible Nanocarriers Cloaked in RBC Membranes for Drug Delivery to Treat Solid Tumors , 2016, Theranostics.

[21]  J. Zimring,et al.  Erythrophagocytosis by plasmacytoid dendritic cells and monocytes is enhanced during inflammation , 2016, Transfusion.

[22]  Chao Zhang,et al.  Immune responses to vaccines delivered by encapsulation into and/or adsorption onto cationic lipid-PLGA hybrid nanoparticles. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[23]  J. Hubbell,et al.  Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigens , 2015, Scientific Reports.

[24]  Zhiping Zhang,et al.  Cell or Cell Membrane-Based Drug Delivery Systems , 2015, Theranostics.

[25]  H. Santos,et al.  Surface chemistry dependent immunostimulative potential of porous silicon nanoplatforms. , 2014, Biomaterials.

[26]  Ronnie H. Fang,et al.  Clearance of pathological antibodies using biomimetic nanoparticles , 2014, Proceedings of the National Academy of Sciences.

[27]  Patrick V. Almeida,et al.  Augmented cellular trafficking and endosomal escape of porous silicon nanoparticles via zwitterionic bilayer polymer surface engineering. , 2014, Biomaterials.

[28]  H. Santos,et al.  Porous silicon nanoparticles for nanomedicine: preparation and biomedical applications. , 2014, Nanomedicine.

[29]  Ronnie H. Fang,et al.  Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. , 2013, Nanoscale.

[30]  Patrick V. Almeida,et al.  The mechanisms of surface chemistry effects of mesoporous silicon nanoparticles on immunotoxicity and biocompatibility. , 2013, Biomaterials.

[31]  Ronnie H. Fang,et al.  Surface Functionalization of Gold Nanoparticles with Red Blood Cell Membranes , 2013, Advanced materials.

[32]  C. Palivan,et al.  Aiding nature's organelles: artificial peroxisomes play their role. , 2013, Nano letters.

[33]  N. Guérin,et al.  Red blood cells as innovative antigen carrier to induce specific immune tolerance. , 2013, International journal of pharmaceutics.

[34]  J. Hubbell,et al.  Engineering antigens for in situ erythrocyte binding induces T-cell deletion , 2012, Proceedings of the National Academy of Sciences.

[35]  F. Granucci,et al.  Migratory, and not lymphoid-resident, dendritic cells maintain peripheral self-tolerance and prevent autoimmunity via induction of iTreg cells. , 2012, Blood.

[36]  Ronnie H. Fang,et al.  Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform , 2011, Proceedings of the National Academy of Sciences.

[37]  C. Palivan,et al.  Biocompatible functionalization of polymersome surfaces: a new approach to surface immobilization and cell targeting using polymersomes. , 2011, Journal of the American Chemical Society.

[38]  Vesa-Pekka Lehto,et al.  Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. , 2010, ACS nano.

[39]  Samir Mitragotri,et al.  Red blood cell-mimicking synthetic biomaterial particles , 2009, Proceedings of the National Academy of Sciences.

[40]  Roland Schauer,et al.  Sialic acids as regulators of molecular and cellular interactions , 2009, Current Opinion in Structural Biology.

[41]  Fabian Itel,et al.  Monolayer interactions between lipids and amphiphilic block copolymers. , 2009, Langmuir : the ACS journal of surfaces and colloids.

[42]  R. Kedl,et al.  Mechanism of T cell tolerance induction by murine hepatic Kupffer cells , 2008, Hepatology.

[43]  R. Kontermann,et al.  Cytotoxic T Lymphocytes Responding to Low Dose TRP2 Antigen are Induced Against B16 Melanoma by Liposome-encapsulated TRP2 Peptide and CpG DNA Adjuvant , 2006, Journal of immunotherapy.

[44]  K. Black,et al.  Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy , 2005, Oncogene.

[45]  Wolfgang Meier,et al.  Block copolymer vesicles—using concepts from polymer chemistry to mimic biomembranes , 2005 .

[46]  Laura Chiarantini,et al.  Erythrocytes deliver Tat to interferon‐γ‐treated human dendritic cells for efficient initiation of specific type 1 immune responses in vitro , 2002, Journal of leukocyte biology.

[47]  E. Appella,et al.  Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes , 1996, The Journal of experimental medicine.

[48]  I. Jackson,et al.  A second tyrosinase‐related protein, TRP‐2, is a melanogenic enzyme termed DOPAchrome tautomerase. , 1992, The EMBO journal.

[49]  W. Swat,et al.  Detection of apoptosis of immature CD4+8+ thymocytes by flow cytometry. , 1991, Journal of immunological methods.

[50]  R. Schwartz,et al.  Antigen presentation by chemically modified splenocytes induces antigen- specific T cell unresponsiveness in vitro and in vivo , 1987, The Journal of experimental medicine.

[51]  J. Oncley,et al.  The contribution of sialic acid to the surface charge of the erythrocyte. , 1962, The Journal of biological chemistry.